Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following <scp>Two‐Dose SARS</scp>–<scp>CoV</scp>‐2 Messenger <scp>RNA</scp> Vaccination

Abstract

Flares of underlying RMD following SARS-CoV-2 vaccination were uncommon. There were no reports of severe flares. Local and systemic reactions typically did not interfere with daily activity. These early safety data can help address vaccine hesitancy in RMD patients.